Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 1 von 37
Journal of experimental & clinical cancer research, 2011-10, Vol.30 (1), p.91-91, Article 91
2011
Volltextzugriff (PDF)

Details

Autor(en) / Beteiligte
Titel
Platinum resistance in breast and ovarian cancer cell lines
Ist Teil von
  • Journal of experimental & clinical cancer research, 2011-10, Vol.30 (1), p.91-91, Article 91
Ort / Verlag
England: BioMed Central
Erscheinungsjahr
2011
Quelle
Elektronische Zeitschriftenbibliothek (Open access)
Beschreibungen/Notizen
  • Breast and ovarian cancers are among the 10 leading cancer types in females with mortalities of 15% and 6%, respectively. Despite tremendous efforts to conquer malignant diseases, the war on cancer declared by Richard Nixon four decades ago seems to be lost. Approximately 21,800 women in the US will be diagnosed with ovarian cancer in 2011. Therefore, its incidence is relatively low compared to breast cancer with 207.090 prognosed cases in 2011. However, overall survival unmasks ovarian cancer as the most deadly gynecological neoplasia. Platinum-based chemotherapy is emerging as an upcoming treatment modality especially in triple negative breast cancer. However, in ovarian cancer Platinum-complexes for a long time are established as first line treatment. Emergence of a resistant phenotype is a major hurdle in curative cancer therapy approaches and many scientists around the world are focussing on this issue. This review covers new findings in this field during the past decade.
Sprache
Englisch
Identifikatoren
ISSN: 1756-9966, 0392-9078
eISSN: 1756-9966
DOI: 10.1186/1756-9966-30-91
Titel-ID: cdi_doaj_primary_oai_doaj_org_article_65088b0e2d9c44608efb5e5bf501f026

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX